1910 Genetics
1910 Genetics, based in Cambridge, MA, integrates AI with proprietary data to advance drug discovery in neurological, autoimmune diseases, and cancer, aiming to make undruggable targets obsolete.
Company Overview
1910 Genetics is a healthcare company based in Cambridge, MA, USA. The company operates in the therapeutics sub-industry and has a team size of 14. It integrates artificial intelligence with three proprietary data streams: computational data, wet lab proxy biological data, and wet lab ground truth biological data. The company delivers novel drug candidates and software solutions to leading pharma and tech partners and advances its internal pipeline targeting neurological, autoimmune diseases, and cancer. 1910 Genetics is a member of the Y Combinator batch W19 and operates in the USA and Canada.
Multimodal AI Drug Discovery Platform
1910 Genetics has developed a multimodal AI platform that leverages laboratory automation to advance both small and large molecule drug discovery. This platform aims to make previously undruggable targets a viable focus by integrating computational data, proxy biological data, and ground truth biological data. Utilizing this technology, 1910 Genetics strives to accelerate the pace of drug discovery and bring innovative solutions to the healthcare industry.
Investment and Funding
1910 Genetics has garnered support from a range of prestigious investors, including Microsoft, Playground Global, FoundersX, Y Combinator, and Scientia Ventures. These investments enable the company to continue developing its AI-driven drug discovery technologies and expand its capabilities within the healthcare sector.
Media Coverage
1910 Genetics has been featured in a range of notable media outlets, attesting to its impact and innovation within the healthcare industry. Publications such as Forbes, Science Magazine, Endpoints News, Business Insider, WSJ, Microsoft Blog, TechCrunch, and GEN have covered the company's advancements and milestones, highlighting its role in integrating AI with drug discovery.